Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Glenmark Pharmaceuticals Limited
GLENMARK | NSE
2,108.90
INR69.20
3.39%
GLENMARK | NSE
About Glenmark Pharmaceuticals Limited
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
31/03/2024
As of date
05/03/2026
Close
2,108.90
Open
2,042.20
High
2,118.90
Low
2,042.20
Glenmark Pharmaceuticals Limited together with its subsidiaries develops manufactures and markets pharmaceutical products in India North America Latin America Europe Japan and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology respiratory and oncology; and various active pharmaceutical ingredients. Its product pipeline includes GBR 310 a biosimilar candidate which is in Phase 2 clinical trial for the treatment of asthma and chronic idiopathic urticaria; and GRC 39815 a retinoid-related orphan receptor gamma t (ROR"t) inverse agonist which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; GRC 17536 a targeting transient receptor potential ankyrin 1 inhibitor which is in Phase 2 clinical trial for the treatment of diabetic peripheral neuropathy; and GRC 54276 a hematopoietic progenitor kinase 1 inhibitor which is in Phase 1 clinical trial for the treatment of solid tumors. The company's pipeline also comprises ISB 1342 CD38 X CD3 bispecific antibody which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442 a CD38 x CD47 immune cell engager which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880 a IL-1RAP antibody which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830 a OX40 antagonist which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition it offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai India."
View LessGLENMARK | NSE
Risk
26.6
Sharpe
1.93
Luna's Score
66/100
Recommendation
Buy
Luna says (GLENMARK | NSE)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low 6-Month Volatility (<30%)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
31.1%1 month
26.6%3 months
25.5%6 months
24.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
14.90
Price to book
6.24
Debt to equity
0.16
Debt to assets
0.09
Ent. to EBITDA
41.01
Ent. to rev.
4.17
PEG
-
Other Fundamentals
EBITDA
23.44B
MarketCap
595.11B
MarketCap(USD)
6.48B
Div. yield
0.14
Op. margin
14.50
Erngs. growth
127.10
Rev. growth
-4.60
Ret. on equity
-20.70
Short ratio
-
Short perc.
-
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
160.60
Range1M
248.80
Range3M
317.80
Volumes: Market Activity
Rel. volume
1.20
Price X volume
1.10B
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 41.01 | 24.85 | Expensive |
| Ent. to Revenue | 4.17 | 11.40 | Cheaper |
| PE Ratio | - | 51.36 | - |
| Price to Book | 6.24 | 6.83 | Par |
| Dividend Yield | 0.14 | 0.52 | Poor |
| Std. Deviation (3M) | 25.51 | 42.17 | Lower Risk |
| Debt to Equity | 0.16 | 0.35 | Cheaper |
| Debt to Assets | 0.09 | 0.17 | Cheaper |
| Market Cap | 595.11B | 290.82B | Market Leader |
